reptides › weight loss › semaglutide

semaglutide

A GLP-1 receptor agonist with current US injection and oral products for distinct labeled uses.

tier S · weight loss · 14.9% STEP 1 mean weight change

verdict

Strong obesity, cardiovascular, kidney, and MASH evidence, but each result belongs to its own product, route, population, and label.

if you are comparing current US products: Wegovy injection, Wegovy tablets, Wegovy HD injection, Ozempic injection, Ozempic tablets, and Rybelsus tablets are separate label records. Rybelsus and Ozempic tablets are not substitutable milligram for milligram.

if you are asking what happened after STEP 1 stopped: In the 327-person STEP 1 extension, participants regained about two-thirds of their prior weight loss during the year after semaglutide and lifestyle treatment ended. That finding is not from STEP 4.

if you are asking about body composition: The STEP 1 DXA substudy reported a 9.7 percent fall in lean mass from baseline. It did not measure muscle directly, and 9.7 percent was not the share of total weight loss.

This is an evidence record, not a dosing recommendation.

what it is

Semaglutide is a GLP-1 receptor agonist. Current US products include Wegovy injection and tablets, Wegovy HD injection, Ozempic injection and tablets, and Rybelsus tablets. Their routes, strengths, and labeled uses are product specific.

key facts

  • molecular weight: ~4113.6 Da
  • amino acids: 31 aa
  • half-life: ~1 week
  • type: acylated GLP-1 receptor agonist

frequently asked questions

Which semaglutide products are currently approved in the US?

Wegovy is available as injection and oral tablets, including a higher-dose Wegovy HD injection record. Ozempic has distinct injection and tablet records. Rybelsus is a separate tablet product, and its doses are not interchangeable milligram for milligram with Ozempic tablets.

Where does the two-thirds regain figure come from?

It comes from the exploratory STEP 1 extension after treatment withdrawal, not from STEP 4.

Does the STEP 1 substudy show muscle loss?

It shows a 9.7 percent reduction in DXA lean mass from baseline. The study did not measure muscle directly.

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.

reptides.